NCT06309589 is a NA clinical trial of Vitamin D in Primary Biliary Cholangitis, sponsored by Yilihamu·Abilitifu.

Who is sponsoring NCT06309589?

NCT06309589 is sponsored by Yilihamu·Abilitifu.

What drugs are being tested in NCT06309589?

Interventions in NCT06309589: Vitamin D.

What condition does NCT06309589 study?

NCT06309589 studies Primary Biliary Cholangitis.

Is NCT06309589 still recruiting?

NCT06309589 is currently completed. Last updated 13 March 2024.

Last reviewed 2024-03-13 · How we verify

NCT06309589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness of Combining Ursodeoxycholic Acid With Vitamin D in Treating Patients With Primary Biliary Cholangitis

Completed NA Last updated 13 March 2024

What this trial tests

NA trial testing Vitamin D in Primary Biliary Cholangitis in 60 participants. Completed in 31 December 2023.

Timeline

1 May 2021

Primary endpoint
30 September 2023

31 December 2023

Quick facts

Lead sponsor	Yilihamu·Abilitifu
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 May 2021
Primary completion	30 September 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Vitamin D

Conditions studied

Primary Biliary Cholangitis — all drugs for Primary Biliary Cholangitis →

Sponsor

Yilihamu·Abilitifu

Who can join

18 and older, any sex, with Primary Biliary Cholangitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare in the effectiveness of combining ursodeoxycholic acid and vitamin D in treating patients with primary biliary cholangitis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Hepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma Pathology.
Cheon I, Kim M, Kim KH, Ko S. · · 2025 · cited 2× · PMID 39326734 · DOI 10.1016/j.ajpath.2024.07.023
Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit.
Song Y, Wang H, Du S, Li Y, et al · · 2026 · PMID 41958671 · DOI 10.3389/fimmu.2026.1766177
The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial.
Abulitifu Y, Maimaiti M, Zhao F, Adilijiang M, et al · · 2025 · PMID 40676542 · DOI 10.1186/s12876-025-04118-0
The Role of Vitamin D in Rare Diseases-A Clinical Review.
Ducki C, Wojtkiewicz M, Bartoszewicz M, Fiedor P. · · 2025 · PMID 40149535 · DOI 10.3390/biomedicines13030558

Verify or expand the search:

Other trials of Vitamin D

Trials testing the same drug.

NCT07366086 — Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta · Phase 3 · recruiting
NCT07458815 — Vitamin D for Acute Intracerebral Hemorrhage · NA · not yet recruiting
NCT07491965 — Association Between Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency . · not yet recruiting
NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
NCT07293910 — Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Py · Phase 2 · recruiting

Other recruiting trials for Primary Biliary Cholangitis

Currently open trials in the same condition.

NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
NCT07282353 — A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA · Phase 3 · recruiting
NCT06730061 — A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) · Phase 3 · active not recruiting
NCT06447168 — A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholang · recruiting
NCT06427395 — Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06309589 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yilihamu·Abilitifu
Last refreshed: 13 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06309589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing